论文部分内容阅读
Moricizine是一新的抗心律失常药,在某些方面有别于其他药理作用相似的化合物。该化合物,即10-(3-吗啉代丙酰)-吩噻嗪-2-氨甲酸乙酯的早期研究表明,吗啉基边链是活性必需基团。作为一个可能的治疗剂,对Moricizine的研究正在进行之中,Sioldoway等人已报道了有关的临床疗效。该药口服吸收良好,经肝脏首过代谢后可检出30余种代谢物,尽管该药的半衰期为2～6h,但其抗心律失常作用持续时间较长,表明其某些代谢物也具有抗心律失常作用。该作用的加强似乎与代谢物的肝脏循环有关。鉴于许多心律失常患者可能同时服用其
Moricizine is a new anti-arrhythmic drug that differs in some respects from other compounds with similar pharmacological effects. Earlier studies of this compound, ethyl 10- (3-morpholinopropionyl) -phenothiazine-2-carboxylate, showed that morpholino side chains are an essential group of activity. As a potential therapeutic, research into Moricizine is underway and Sioldoway et al. Have reported relevant clinical outcomes. The drug is well absorbed orally, and more than 30 metabolites can be detected after the first metabolism of the liver. Although the half-life of the drug is 2-6h, the anti-arrhythmic action lasts longer, indicating that some of its metabolites also have Anti-arrhythmic effect. This enhancement appears to be related to the liver circulation of metabolites. Given that many arrhythmias patients may take it at the same time